Navigation Links
NUCRYST announces 2009 first quarter financial results
Date:5/6/2009

PRINCETON, NJ, May 6 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals Corp., a developer and manufacturer of medical products that fight infection and inflammation, today announced its financial results for the first quarter of 2009.

For the quarter ended March 31, 2009, NUCRYST reported a net loss of $1.1 million, or $0.06 cents per share, on revenues of $4.1 million. This compares to a net loss of $2.2 million, or $0.12 cents per share, on revenues of $5.2 million in the first quarter of 2008.

At March 31, 2009, NUCRYST had $8.4 million in cash and cash equivalents, compared to $23.4 million at December 31, 2008. In the first quarter of 2009, NUCRYST completed a $14.7 million, or $0.80 per share, cash distribution to NUCRYST shareholders.

"With the return of capital to our shareholders in the first quarter of 2009, we are taking the necessary steps to reduce our cost structure to an appropriate level," said David B. Holtz, Interim President and Chief Executive Officer, and Chief Financial Officer of NUCRYST. "We remain focused on driving the Company towards a sustainable level of profitability while continuing to explore strategic alternatives for the business."

First quarter financial analysis

NUCRYST's total revenue which consists of wound care product revenues less the manufacturing cost rebate for the first quarter of 2009 decreased to $4.1 million compared to $5.2 million in the first quarter of 2008. The decline was due to lower product shipments in the first quarter of 2009 and lower royalty revenues as a result of lower US dollar sales of Acticoat(TM) reported by Smith & Nephew plc. Smith & Nephew's reported Acticoat(TM) sales were negatively impacted by the strengthening U.S. dollar.

Gross margin on product revenues was 46% in the first quarter of 2009, compared to 21% in the first quarter of 2008. The improvement is primarily the result of cost reductions achieved through ma
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
2. NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results
3. NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
4. NUCRYST appoints interim CEO
5. NUCRYST Pharmaceuticals appoints a new director
6. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
7. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
8. NUCRYST Receives Deficiency Notice from NASDAQ
9. NUCRYST Pharmaceuticals to Release Second Quarter 2008 Financial Results on Tuesday, August 12, 2008
10. NUCRYST Appoints David B. Holtz as Vice President and Chief Financial Officer
11. NUCRYST Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , ... September 02, 2015 , ... ... imaging, content, records and case management solutions and services to both government and ... Image Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. ...
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... designed for people to comfortably hold a tablet while reducing the likelihood of it ...
(Date:9/2/2015)... ... , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, has ... year. Less than 5 % of this year’s 5000 honorees share the “six-time” recognition; ... 3-year revenue growth rate of 65% sustained its most recent achievement. As an Inc. ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to ... are being launched, and mobile device usage as a whole is something people around ... personal lives. What's more people are expecting mobile versions of their favorite software. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... For many men, the first thing they notice when they ... forced to wear a looser fitting shirt with a collar that doesn’t close against the ... between their collar and skin all day because it’s uncomfortable. Now men in suits ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... of hope for visually- impaired patients.Retinal cell transplants can ... possibilities for them. Researchers at the University of Texas, ... a predisposition to blindness.// Experiments showed that the rats ... animals with normal vision. ,This is an ...
... Coffee is a very good stimulant in day to day ... memory performance that happens as the day progresses. During the ... adults compared to late afternoon.// For researchers at the University ... memory performance throughout the day. ,They had about ...
... that if women drink too much coffee during pregnancy can ... fits.//Studies have found that caffeine may be linked to the ... have been briefly starved of oxygen. ,A research team ... cells from the hippocampus, a part of the brain that ...
... Andhra Pradesh chief minister Chandrababu Naidu has set into ... in the port town of Vishakhapatnam. By providing world-class ... to attract global pharmaceutical companies to the city for ... 2005. The ‘Pharma City’ will be developed by private ...
... the disease gradually ended around the world. But stockpiles ... US, Russia and possibly other nations.// Recent fears of ... used to introduce the potentially deadly disease into the ... a potential outbreak. If introduced into America or Europe, ...
... a diet rich in butter and other fats, has led ... staple of the French diet. //Scientists say they have discovered ... known as polyphenols. ,Polyphenols inhibit the production ... Polyphenols in red wine decreases the amount of the peptide ...
Cached Medicine News:
(Date:9/2/2015)... Sept. 2, 2015 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... the Company,s subsidiary Guizhou Taibang Biological Products Co., ... agreement (the "Agreement") with Xinjiang Deyuan Bioengineering Co., ... Agreement allows Guizhou Taibang to source no less ...
(Date:9/2/2015)... NEW YORK , Sept. 2, 2015 ... developing novel therapies for the treatment of chronic pain, ... investor meetings at both the FBR Second Annual Healthcare ... are as follows: FBR Second Annual Healthcare ... Seasons, Boston No presentation, ...
(Date:9/2/2015)... , Sept. 2, 2015  Kastle Therapeutics ... and commercializing pharmaceuticals for diseases with high unmet ... 3 executives to key commercial operating positions. ... Vice President, Commercial; Sean was previously Global Marketing ... been appointed as Director, Commercial Strategy and Analytics; ...
Breaking Medicine Technology:China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 2China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 3China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 4China Biologic Enters into Strategic Collaboration Agreement to Source Raw Materials 5Relmada Therapeutics to Participate in Two Upcoming Investor Conferences 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 2Kastle Therapeutics Announces Key Additions to Commercial Leadership 3
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: